Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 20/20 | 1.00 |
| ▸ | FLT4 | P35916 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489707 | 0.92 | FLT1 (0.86) | FLT1FLT4KDR | |
| SCHEMBL31310429 | 0.91 | FLT1 (0.83) | FLT1FLT4KDR | |
| SCHEMBL5958926 | 0.91 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL31310442 | 0.91 | FLT1 (0.83) | FLT1FLT4KDR | |
| SCHEMBL5959146 | 0.91 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL5489698 | 0.91 | FLT1 (0.83) | FLT1FLT4KDR | |
| SCHEMBL5958902 | 0.91 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL5491628 | 0.91 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL31060564 | 0.91 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL5958979 | 0.89 | FLT1 (1.00) | FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291592-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-18 | — | — | US | claimed |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| EP-2015070-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | US | claimed |
| EP-1862179-A1 | NOVEL USE OF SULFONAMIDE COMPOUND IN COMBINATION WITH ANGIOGENESIS INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2007-12-05 | — | — | EP | claimed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| EP-1859797-A1 | NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-20220151995-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND SUPPRESSING METASTASIS, CONTAINING SULFONAMIDE-BASED COMPOUND AS ACTIVE INGREDIENT | EXOSTEMTECH CO., LTD (KR) | 2022-05-19 | — | — | US | disclosed |
| WO-2021151974-A1 | INTERFERING WITH MRNA SPLICING TO ENHANCE RESPONSE TO CHECKPOINT IMMUNOTHERAPIES. | STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2021-08-05 | — | — | WO | disclosed |
| US-20190008876-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND SUPPRESSING METASTASIS, CONTAINING SULFONAMIDE-BASED COMPOUND AS ACTIVE INGREDIENT | EXOSTEMTECH CO., LTD (KR) | 2019-01-10 | — | — | US | disclosed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-1401806-B1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | LILLY CO ELI (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY | 2004-08-12 | — | — | US | disclosed |
| EP-1401806-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098848-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | FLT1 76/4885FLT4 51/4885KDR 31/4885 |
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | GLS2, GLS, MCL1 | FLT1 1396/4885FLT4 1421/4885KDR 2630/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | FLT1 3/4885FLT4 1/4885KDR 2/4885 |
| US-20220151995-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND SUPPRESSING METASTASIS, CONTAINING SULFONAMIDE-BASED COMPOUND AS ACTIVE INGREDIENT | SULT2A1, STS, SULT1A1 | FLT1 2565/4885FLT4 2753/4885KDR 2533/4885 |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | TOP1, TOP2A, TOP2B | FLT1 220/4885FLT4 181/4885KDR 231/4885 |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | KDR, FLT4, FLT1 | FLT1 3/4885FLT4 2/4885KDR 1/4885 |
| US-20190008876-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND SUPPRESSING METASTASIS, CONTAINING SULFONAMIDE-BASED COMPOUND AS ACTIVE INGREDIENT | SULT2A1, STS, SULT1A1 | FLT1 2565/4885FLT4 2753/4885KDR 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.